The DOI matches its Crossref record.
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes
Open accessAbstract
Ten human ovarian carcinoma cell lines have been studied as a potential in vitro screen for the development of novel anticancer platinum complexes. Lines have been established and developed both from solid and ascitic tumours, from pretreated and untreated patients, and are available at a range of in vitro passage numbers. The biological properties of the lines were consistent with them being human, epithelial and of ovarian carcinoma origin. Using a tritiated thymidine or leucine uptake method, and a 96 hour continuous drug exposure, the lines have been calibrated against four platinum-containing chemotherapeutic agents: cisplatin, iproplatin, carboplatin and tetraplatin. Striking differences in cytotoxicity were observed across the lines for each agent. Some lines were consistently resistant, others generally sensitive, whereas some showed clear evidence of differential sensitivity to a particular agent. Statistical analysis (Spearman rank correlation) involving the six possible pairings of drugs showed that cisplatin, iproplatin and carboplatin elicit a very similar pattern of response in these lines whereas tetraplatin elicits a completely different response pattern. Similar cytotoxicity values were obtained using a soft agar cloning assay. Results using a tetrazolium dye reduction assay, however, gave somewhat higher and more variable values, particularly with tetraplatin. The thymidine uptake assay will be adopted in further studies on a selected panel of six lines. This panel encompasses the spectra of sensitivities identified for each of the four agents against the original ten lines and may provide a useful screening facility for the development of novel platinum drugs, in that it detects both cell line-determined and structure-determined differences in cytotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
Myungjin Lee, J., Mhawech-Fauceglia, P., Lee, N., Cristina Parsanian, L., Gail Lin, Y., Andrew Gayther, S., & Lawrenson, K. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.41 · Cited by 301
Preclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
Self-citation
Metadata
- Authors
- Hills, C., Kelland, L., Abel, G., Siracky, J., Wilson, A., & Harrap, K.
- Venue
- British Journal of Cancer
- Published
- 1989-04
- Volume
- 59
- Issue
- 4
- Pages
- 527-534
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2003003988
- Cited by
- 183
- References
- 0
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. https://app.cochat.ai/papers/10.1038/bjc.1989.108
- The paper
- Hills, C., Kelland, L., Abel, G., Siracky, J., Wilson, A., & Harrap, K. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. British Journal of Cancer. https://doi.org/10.1038/bjc.1989.108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.